News
We are hiring for our newly funded NCI U01 to study obesity, protective immunity, and breast cancer risk.
|Come work with us! Link to posting here.
We can’t wait to work with NCI’s Metabolic Dysregulation and Cancer Risk Program: A Transdisciplinary Approach to Obesity-Associated Cancer Research program.
|Very excited to conduct this work on my project entitled Determining the Contribution of Microbial-Derived Metabolites to Protective Immunity in Obesity-Driven Cancer Risk with MPIs Jeff Rathmell and Joseph Pierre, and many other collaborators. This is a dream project! These studies will increase understanding of obesity-associated cancer risk and point to potential interventions to alleviate… Read More
Check out our new paper led by Dr. Laura Sipe, PhD in eLife on immunotherapy response in pre-clinical models of breast cancer after bariatric surgery
|Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery. Link HERE
Happy Graduation to Dr. Mehdi Chaib, PhD – Commencement 2022
|Mehdi Chaib, PhD (@ChaibImmune) has completed his doctoral studies in the Makowski lab and has joined the lab of Jim Allison, PhD at MD Anderson to complete his post-doctoral studies.
Press release is out for our new R01 to study breast cancer genetics
|UTHSC Team Receives $2 Million For Breast Cancer Genetics Research
Makowski lab receives R01 from NCI to study genetic variants in breast cancer.
|We are happy to announce that Liza Makowski was awarded an R01 from the NCI which scored a 2%. The proposal is entitled “Determining susceptibility loci in triple negative breast cancer using a novel pre-clinical model.” Co-investigators Drs. Rob Williams, Lu Lu, D. Neil Hayes, and David Ashbrook at UTHSC and Dr. Carey Anders at… Read More
Mehdi Chaib awarded F31NRSA Pre-doctoral Fellowship award from the National Cancer Institute (NCI)
|Mehdi Chaib, graduate student in Makowski Lab, was awarded a 3 year F31 predoctoral NRSA fellowship from the NCI in Dec of 2021. His proposal entitled “PKC agonism restricts innate immune suppression and promotes antigen cross-presentation in Triple Negative Breast Cancer” scored a 3%. We are so proud of him! Congratulations!